| Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. | |
| | |
MedLine Citation:
|
PMID: 14586600 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cerebellar syndrome is one of the most disabling developments in multiple sclerosis (MS). In neurodegenerative disorders, cerebellar syndrome is thought to be related to a neurochemical deficit of 5-hydroxytryptamine (5-HT). Previous studies found that a levorotatory form of 5-hydroxytryptophan, a 5-HT precursor, and ondansetron, a 5-HT(3) receptor antagonist, decreased cerebellar symptoms in Friedreich's ataxia and MS. We studied the effect of another 5-HT(3) receptor antagonist, dolasetron mesilate, on cerebellar syndrome in MS patients.Thirty-four MS patients were included in a placebo-controlled double-blind crossover study. They received a single dose of intravenous dolasetron mesilate or placebo. A quantitative evaluation of cerebellar syndrome using the nine-hole peg test and an ataxia score comprising static and kinetic parameters were performed before and after each treatment. No statistical difference was observed in the dolasetron mesilate group, compared with the placebo group. There was, however, inter-individual variability in the treatment response. This double-blind study on cerebellar syndrome in MS patients did not confirm the positive effect of dolasetron mesilate suggested by previous studies. |
| | |
Authors:
|
C Monaca-Charley; T Stojkovic; A Duhamel; J De Seze; D Ferriby; P Vermersch |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of neurology Volume: 250 ISSN: 0340-5354 ISO Abbreviation: J. Neurol. Publication Date: 2003 Oct |
Date Detail:
|
Created Date: 2003-10-30 Completed Date: 2003-12-12 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 0423161 Medline TA: J Neurol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1190-4 Citation Subset: IM |
Affiliation:
|
Clinique neurologique, Hôpital Roger Salengro, CHRU de Lille, 59037 Lille Cedex, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Cerebellar Diseases / drug therapy*, etiology* Cross-Over Studies Double-Blind Method Female Humans Indoles / administration & dosage, therapeutic use* Infusions, Intravenous Male Middle Aged Multiple Sclerosis / complications* Quinolizines / administration & dosage, therapeutic use* Reproducibility of Results Serotonin Antagonists / administration & dosage, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Indoles; 0/Quinolizines; 0/Serotonin Antagonists; 115956-13-3/dolasetron mesylate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Feasibility study of single region lambda chart analysis for pyramidal tract physiology.
Next Document: Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity.